Product image of Mometasonfuroaat Basic Pharma (Mometasone Furoate) supplied by GNH India

Mometasonfuroaat Basic Pharma

Active Ingredient:
Mometasone Furoate
Origin:
EU

Mometasonfuroaat Basic Pharma (Mometasone Furoate)

Mometasone furoate, the active ingredient in Mometasonfuroaat Basic Pharma, is a glucocorticoid presented as a nasal spray for nasal use. It provides anti‑inflammatory relief for allergic rhinitis, including seasonal and perennial forms, in patients who need corticosteroid therapy.

GNH India supplies Mometasonfuroaat Basic Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product meets EU quality standards and is manufactured under strict GMP conditions. Its consistent batch‑to‑batch potency supports reliable clinical outcomes.

Manufacturer / TM Owner

Basic Pharma Manufacturing Bv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mometasone furoate nasal spray is a glucocorticoid that reduces inflammation in the nasal passages for allergic conditions.

  • Allergic rhinitis: reduces nasal congestion, itching, sneezing and rhinorrhea, improving airflow.
  • Seasonal allergic rhinitis: controls symptoms triggered by pollen exposure, providing relief during allergy seasons.
  • Perennial allergic rhinitis: offers year‑round symptom control for indoor allergen‑induced nasal inflammation.

How It Works

  • Mometasone furoate penetrates nasal mucosal cells and binds to intracellular glucocorticoid receptors. The drug‑receptor complex moves to the nucleus and interacts with glucocorticoid response elements, altering gene transcription. This down‑regulates pro‑inflammatory cytokines, chemokines, adhesion molecules and enzymes such as phospholipase A2, resulting in reduced inflammatory cell infiltration and edema in the nasal mucosa.

Side Effects

Mometasone furoate nasal spray may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Nasal irritation or burning.
  • Epistaxis (nosebleeds).
  • Headache.
  • Sore throat.

Serious or Rare Side Effects

  • Nasal septal perforation.
  • Cataracts or increased intra‑ocular pressure.
  • Adrenal suppression with prolonged high‑dose use.

Precautions & Warnings

When using Mometasone furoate nasal spray, consider the following precautions.

  • Hypersensitivity: discontinue if patient experiences rash, swelling or breathing difficulty.
  • Recent nasal surgery or trauma: avoid use until healed.
  • Duration of therapy: limit continuous use to the recommended period, usually not exceeding three months without medical review.
  • Concomitant use with other nasal corticosteroids: avoid to reduce systemic exposure.
  • Systemic effects: monitor for signs of adrenal insufficiency during long‑term high‑dose therapy.
  • Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Mometasone furoate nasal spray can interact with other medicines; awareness of these interactions helps maintain safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure.
  • Concurrent use of other intranasal corticosteroids: additive glucocorticoid effects.

Moderate Interactions (Monitor Closely)

  • Systemic glucocorticoids: may enhance overall corticosteroid activity.
  • Immunosuppressants (e.g., cyclosporine): monitor for increased infection risk.
  • Antiviral agents metabolized by CYP3A4 (e.g., ritonavir): observe for altered drug levels.

Frequently Asked Questions

Mometasonfuroaat Basic Pharma contains mometasone furoate, a nasal corticosteroid indicated for the treatment of allergic rhinitis, including both seasonal and perennial forms. It helps relieve nasal congestion, itching, sneezing and runny nose by reducing inflammation in the nasal passages.

Mometasone furoate binds to intracellular glucocorticoid receptors in nasal mucosal cells. The resulting complex alters gene transcription, suppressing the production of inflammatory cytokines, chemokines and enzymes. This anti‑inflammatory action decreases swelling and mucus production, improving nasal airflow.

The appropriate dose is determined by the prescribing healthcare professional based on the patient’s age, severity of symptoms and treatment response. Typical regimens involve one or two sprays per nostril once daily, but exact instructions should always follow the prescriber’s order.

Safety data in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant. Healthcare providers usually assess the risk‑benefit profile before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mometasone furoate is a high‑potency glucocorticoid with a favorable safety profile when used at recommended doses. Compared with agents such as fluticasone propionate, it offers similar efficacy for allergic rhinitis but may require fewer daily sprays due to its longer residence time in the nasal mucosa.

Store the nasal spray at room temperature, below 25 °C, in its original container. Keep it away from moisture, direct sunlight and extreme heat. Do not freeze the product, and ensure the cap is tightly closed when not in use.

Shake the bottle gently, remove the protective cap and prime the spray if it is the first use. Tilt the head slightly forward, insert the tip into one nostril, close the opposite nostril, and press the pump while breathing in gently. Repeat for the other nostril as directed.

Serious adverse events, although rare, include nasal septal perforation, cataract formation or increased intra‑ocular pressure, and adrenal suppression with prolonged high‑dose therapy. Patients should report persistent nosebleeds, visual changes or symptoms of hormonal imbalance to their healthcare provider promptly.

Individuals with a known hypersensitivity to mometasone furoate or any component of the formulation should avoid the product. It is also contraindicated in patients with active untreated nasal infections, recent nasal surgery or trauma, and in those for whom systemic corticosteroid therapy is contraindicated.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Mometasone Furoate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT